

Table SI. Pathological outcomes of chemotherapy combined with immunotherapy in different subtypes.

Characteristic	LUAD (%)	LUSC (%)	P-value
n	14 (100.00)	17 (100.00)	
pCR	3 (21.43)	10 (58.82)	0.07
MPR	3 (21.43)	2 (11.76)	0.64
Downstaging of T stage	12 (85.71)	16 (94.12)	0.58
Downstaging of N stage	12 (85.71)	15 (88.24)	0.62

LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; pCR, pathologic complete response; MPR, major pathological response.

Table SII. Pathological outcomes of chemotherapy in different subtypes.

Characteristic	LUAD (%)	LUSC (%)	P-value
n	17 (100.00)	19 (100.00)	
pCR	2 (11.76)	4 (21.05)	0.66
MPR	0 (0.00)	1 (5.26)	>0.99
Downstaging of T stage	12 (70.59)	11 (57.89)	0.50
Downstaging of N stage	12 (70.59)	15 (78.95)	0.71

LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; pCR, pathologic complete response; MPR, major pathological response.

Table SIII. Comparison of pathological remission of neoadjuvant chemotherapy and neoadjuvant immunotherapy in LUAD.

Characteristic	Chemotherapy (%)	Chemotherapy combined with immunotherapy (%)	P-value
n	17 (100.00)	14 (100.00)	
pCR	2 (11.76)	3 (21.43)	0.64
MPR	0 (0.00)	5 (35.71)	0.81
Downstaging of T stage	12 (70.59)	12 (85.71)	0.41
Downstaging of N stage	12 (70.59)	12 (85.71)	0.41

LUAD, lung adenocarcinoma; pCR, pathologic complete response; MPR, major pathological response.